Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Girona – page 17

302 clinical trials in Girona, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Girona at a glance
302
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

302 trials in Girona

Open in trial search

Head and neck cancer metastatic

Not recruiting

Study of eftilagimod alpha with pembrolizumab combination therapy for patients with metastatic head and neck cancer who have not received previous treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Eftilagimod Alfa
  • Sponsor:Immutep

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Guselkumab for Patients with Fistulizing Perianal Crohn's Disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Acute myeloid leukaemia

Not recruiting

Study of venetoclax and azacitidine combination treatment for acute myeloid leukemia patients with measurable residual disease after chemotherapy or before stem cell transplant

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Grupo Cooperativo De Estudio Y Tratamiento De Las Leucemias Agudas Y Mielodisplasias

Study on the Effects of FDY-5301 for Patients with Anterior ST-Elevation Myocardial Infarction (Heart Attack)

Not recruiting
Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Iodide
  • Sponsor:Faraday Pharmaceuticals Inc.

Endometrial cancer

Not recruiting

Study on Durvalumab, Paclitaxel, Carboplatin, and Olaparib for Patients with Advanced or Recurrent Endometrial Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Fallopian tube cancer+2

Not recruiting

Study of Nemvaleukin Alfa and Pembrolizumab for Patients with Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Nemvaleukin Alfa
  • Sponsor:Mural Oncology Inc.

Plasma cell myeloma

Not recruiting

Study on Elranatamab and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma After Prior Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Pfizer Inc.

Gastric cancer+1

Not recruiting

Study of Zanidatamab and Tislelizumab Combined with Chemotherapy for Patients with Advanced or Metastatic HER2-positive Gastroesophageal Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Jazz Pharmaceuticals Ireland Limited

Endometrial cancer recurrent

Not recruiting

Study on Durvalumab, Olaparib, and Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer in Spain

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Astrazeneca Farmaceutica Spain S.A.

Breast cancer

Not recruiting

Study on Capivasertib and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer After Standard Treatment Progression

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Capivasertib
  • Sponsor:Astrazeneca Farmaceutica Spain S.A.

Pancreatic carcinoma metastatic

Not recruiting

Study on the Safety and Effectiveness of ABTL0812 with Drug Combination for Patients with Metastatic Pancreatic Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Ability Pharmaceuticals S.A.

Non-small cell lung cancer

Not recruiting

Study on the Safety and Effectiveness of Fianlimab, Cemiplimab, and Chemotherapy in Adults with Resectable Non-Small Cell Lung Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Regeneron Pharmaceuticals Inc.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Girona

What the registry says about research in the country

01 Neurology & Stroke Treatment

Innovative research focusing on acute ischemic stroke treatments, including studies evaluating new therapies to improve functional outcomes and neurological recovery.

  • Stroke recovery assessment
  • Neurological function improvement
  • Reperfusion optimization

Multiple trials exploring breakthrough treatments for patients with cerebral ischemic conditions.

02 Respiratory & Viral Diseases

Comprehensive studies on respiratory infections, including trials for RSV, hMPV, and COVID-19 vaccines, particularly focusing on vulnerable populations.

  • Vaccine efficacy studies
  • Immunogenicity assessment
  • Combined vaccine research

Special attention to developing protective measures for adults over 60 years of age.

03 Oncology Research

Groundbreaking studies in cancer treatment, including trials for breast cancer, prostate cancer, and leukemia using innovative therapeutic approaches.

  • Triple-negative breast cancer therapy
  • Chronic myeloid leukemia treatment
  • Metastatic cancer management

Focus on developing targeted therapies and improving treatment outcomes across various cancer types.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.